Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Novo Nordisk Submits First Recombinant Treatment for Factor XIII Deficiency for U.S. Regulatory Approval

February 23, 2011 By Bio-Medicine.Org

PRINCETON, N.J., Feb. 23, 2011 /PRNewswire/ — Novo Nordisk
announced today that a Biologic License Application (BLA) has been
submitted to the U.S. Food and Drug Administration (FDA) requesting
the approval of a recombinant factor XIII compound (rFXIII) for the
vast majority of patients with congenital factor XIII (FXIII)
deficiency, an inherited bleeding disorder(1). The company
anticipates filing its marketing authorization application to the
European Medicines Agency in Q2 2011.

Currently, FXIII deficient patients are treated with products
derived from human blood plasma(2), which carry an inherent risk of
contamination. Treatments created using recombinant technology are
genetically engineered and not sourced from human blood or plasma.
The use of this technology in the development of treatments helps
to reduce the potential risk of transmitting blood-borne
illnesses.

Patients with congenital FXIII deficiency have a lifelong
susceptibility towards bleeding problems, including spontaneous
intracranial hemorrhage. Caused by a lack of the protein clotting
factor XIII, FXIII congenital deficiency has a prevalence of one
case per two million people(2). With an estimated 600 diagnosed
patients worldwide, FXIII deficiency is considered one of the
rarest bleeding disorders(3).

“Novo Nordisk is committed to serving the bleeding disorder
community, and this submission marks a major milestone in the
expansion of our product offerings to this patient group,” said
Eddie Williams, Vice President of Biopharmaceuticals at Novo
Nordisk. “The development of a treatment that does not depend on
blood products is an important step for the hundreds of patients
affected worldwide by congenital FXIII deficiency.”

Positive results from a phase 3 trial examining the efficacy and
safety of rFXIII for the prevention of bleeds associated with
congenital FXIII deficiency showed that when compared to a historic
control group of individuals who did not receive

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech